ArticleFrontiers in immunology2025
Impact of the prognostic nutritional index on the recompensation of patients with decompensated primary biliary cholangitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nutrition and immunity are associated with the progression of primary biliary cholangitis (PBC); however, the connection between these factors and the prognosis of patients with decompensated PBC remains unclear. Methods: This study adopted a retrospective cohort design, enrolling patients with decompensated PBC who received standard-dose ursodeoxycholic acid treatment. The prognostic nutritional index (PNI) was calculated based on lymphocyte count and albumin levels at admission. The Cox proportional hazards model was used to analyze the impact of PNI on the recompensation of patients with decompensated liver cirrhosis. Results: A total of 413 patients with decompensated PBC were included, with a mean age of 60.34 ± 11.57 years, of whom 343 (83.1%) were female. During the follow-up period, 119 patients (28.8%) achieved recompensation. The median baseline PNI was higher in the recompensation group [44.5, interquartile range (IQR): 39.5-49.3] than in the non-recompensation group (33.9, IQR: 29.8-38.2). In the fully adjusted model, a higher baseline PNI score was associated with an increased probability of recompensation [hazard ratio (HR): 1.11, 95% CI: 1.08-1.15]. Subgroup analysis showed that baseline PNI was significantly associated with recompensation in patients with ascites (HR: 1.15, 95% CI: 1.11-1.20), without ascites (HR: 1.06, 95% CI: 1.01-1.12), with bleeding (HR: 1.10, 95% CI: 1.03-1.17), and without bleeding (HR: 1.13, 95% CI: 1.08-1.17). Trend analysis showed that PNI, as a continuous variable, was significantly positively correlated with the likelihood of recompensation (HR: 1.11, 95% CI: 1.08-1.15). Sensitivity analysis confirmed that after excluding patients with comorbidities, the association between PNI and recompensation remained stable (HR: 1.11, 95% CI: 1.07-1.15). Conclusions: PNI is an independent protective factor for recompensation in patients with decompensated PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.